As most of you already know, drugs whose patent has expired are likely to be developed in the form of Generic drug, that is, manufacturing the same substance or active principle, with the same safety, quality and efficacy than the brand drug, but with significant savings for public health systems.

In the case of biological medicines, treatments based on biotechnology with very complex cell lines that are produced from living organisms capable of modifying the biological response to the disease in a different way in each patient, the biosimilar drugs they are gaining greater prominence day after day, since more and more pharmaceutical laboratories are betting on this product. Biosimilars, like generic medicines, can mean significant savings for the coffers of public health systems, which in any case entails a benefit for patients.

However, the biosimilars they should not be confused with the generic drugs, since, as their name indicates, they are not exactly the same as their reference biologicals, although once they have passed the relevant controls, they guarantee the same effectiveness as these.

To clarify these concepts a little more, we offer you an interesting video produced by Amgen, a pharmaceutical laboratory specializing in biotechnological products.